Form 4: Centessa Pharmaceuticals CEO Saurabh Saha Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Centessa Pharmaceuticals CEO Saurabh Saha sold ordinary shares between August 20 and August 22, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Saurabh Saha, CEO of Centessa Pharmaceuticals plc, reported the sale of ordinary shares between August 20 and August 22, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on May 16, 2024.
- On August 20, 2024, 4,169 shares were sold at a weighted average price of $12.3215, with prices ranging from $12.23 to $12.58.
- On August 21, 2024, 3,674 shares were sold at a weighted average price of $12.2453, with prices ranging from $12.23 to $12.32.
- On August 22, 2024, 506 shares were sold at a price of $12.23.
- Following these transactions, Saha directly owns 823,575 ordinary shares and indirectly owns 38,000 shares through a trust where he and his spouse are trustees.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The share sales may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| 08/20/2024 | Date of first reported transaction |
| 08/21/2024 | Date of second reported transaction |
| 08/22/2024 | Date of third reported transaction and filing date of the Form 4 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.